Inteligencia Artificial para búsqueda de información científica

Fernanda Cuneo

¿Qué es?

La inteligencia artificial (IA) es un campo de la informática que desarrolla sistemas capaces de realizar tareas que, tradicionalmente, requieren inteligencia humana. Estas tareas incluyen aprender, razonar, resolver problemas, interpretar lenguaje natural y tomar decisiones.

Definición técnica

La Organización Panamericana de la Salud (OPS) define la inteligencia artificial (IA) como "la ciencia que desarrolla máquinas para hacer tareas que requerirían inteligencia humana". Esta definición abarca métodos que permiten ejecutar tareas que normalmente requieren inteligencia humana, incluyendo tanto la representación del conocimiento humano (IA simbólica) como el uso de datos para generar conocimiento (IA basada en aprendizaje automático). Además, engloba múltiples áreas de aplicación, como el procesamiento del lenguaje natural, la visión artificial, la robótica y el procesamiento de voz, entre otras



¿Cómo Funciona?

- La IA no "piensa" como los humanos, pero utiliza datos y algoritmos para simular procesos de razonamiento.
- Sus pilares fundamentales incluyen:
- Datos: La IA necesita grandes cantidades de datos para aprender. Por ejemplo: Un sistema de reconocimiento facial analiza millones de fotos para distinguir características únicas de un rostro.
- Algoritmos: Un algoritmo es un conjunto de instrucciones que le dice al sistema cómo analizar los datos. Ejemplo: En Netflix, los algoritmos analizan tus preferencias para recomendarte películas o series.
- Aprendizaje Automático (Machine Learning): Es una rama de la IA que permite que las máquinas aprendan por sí mismas sin ser programadas explícitamente. Ejemplo: Un modelo de machine learning puede predecir el clima al analizar patrones históricos y datos actuales.
- Aprendizaje Profundo (Deep Learning): Es un tipo avanzado de aprendizaje automático que utiliza redes neuronales artificiales, inspiradas en cómo funciona el cerebro humano. Ejemplo: Los autos autónomos de Tesla utilizan redes neuronales para tomar decisiones de conducción en tiempo real.


Herramientas IA para buscar información médica













Scispace




▶ Diseñada para facilitar el acceso a bibliografía científica. Permite buscar gran cantidad de artículos y extraer información relevante, genera resúmenes automáticos y proporciona definiciones claras de términos médicos complejos.

https://pro.campus.sanofi/es/inteligencia-artificial/herramientas/top-herramientas-inteligencia-artificial-articulos-medicos

Scispace







Scispace



La plataforma de investigación más rápida de la historia

Herramientas Al todo en uno para estudiantes e investigadores.





Literature Review

⊕English (en) ▼

Hypertension AND Losartan AND Methyldopa

Standard

High Quality


Deep Review


→


Try searching for:

- What are the comparative effects of Losartan and Methyldopa on blood pressure management in patients with hypertension?
- Q How does the combination of Losartan and Methyldopa impact cardiovascular outcomes in hypertensive patients?
- What are the potential side effects and interactions of co-administering Losartan and Methyldopa in the treatment of hypertension?

Tip: If you're asking a question, add a question mark (?) at the end to get better results








Research rabbit





- Diseñada para agilizar el proceso de revisión de la literatura.
- Ofrece una exploración de la bibliografía científica mediante visualizaciones interactivas. Su tecnología permite a quien la utiliza identificar conexiones entre artículos, autores y líneas de investigación. Facilita así la investigación sobre un tema y otorga una visión general de cómo evoluciona el campo de estudio.

https://pro.campus.sanofi/es/inteligencia-artificial/herramientas/top-herramientas-inteligencia-artificial-articulos-medicos









4 selected papers



Beverly Winikoff

Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.

The Lancet

L 84

Summary Background Hypertension is the most common medical disorder in pregnancy, complicating one in ten pregnancies. Treatment of severely increased blood pressure is widely recommended to reduce the risk for maternal complications. Regimens for the acute treatment of severe hypertension typically include intravenous medications. Although effective, these drugs require venous access and careful fetal monitoring and might not be feasible in busy or lowresource environments. We therefore aimed to compare the efficacy and safety of three oral drugs, labetalol, nifedipine retard, and methyldopa for the management of severe hypertension in pregnancy. Methods In this multicentre. parallel-group, open-label, randomised controlled trial, we compared these oral antihypertensives in two public hospitals in Nagpur, India. Pregnant women were eligible for the trial if they were aged at least 18 years; they were pregnant with fetuses that had reached a gestational age of at least 28 weeks: they required pharmacological blood pressure control for severe hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg); and were able to swallow oral medications. Women were randomly assigned to receive 10 mg oral nifedipine, 200 mg oral labetalol (hourly, in both of which the dose could be escalated if hypertension was maintained), or 1000 mg methyldopa (a single dose, without dose escalation). Masking of participants, study investigators, and care providers to group allocation was not possible because

Articles

Oral antihypertensive regimens (nifedipine retard, labetalol, M 🕻 🕕 and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial





Thomas Easterling, Shuchita Mundle, Hillary Bracken, Seema Parvekar, Sulabha Mool, Laura A Magee, Peter von Dadelszen, Tara Shochet, Beverly Winikoff

oa

Summary

Background Hypertension is the most common medical disorder in pregnancy, complicating one in ten pregnancies. Treatment of severely increased blood pressure is widely recommended to reduce the risk for maternal complications. Regimens for the acute treatment of severe hypertension typically include intravenous medications. Although effective, these drugs require venous access and careful fetal monitoring and might not be feasible in busy or lowresource environments. We therefore aimed to compare the efficacy and safety of three oral drugs, labetalol, nifedipine retard, and methyldopa for the management of severe hypertension in pregnancy.

Methods In this multicentre, parallel-group, open-label, randomised controlled trial, we compared these oral antihypertensives in two public hospitals in Nagpur, India. Pregnant women were eligible for the trial if they were aged at least 18 years; they were pregnant with fetuses that had reached a gestational age of at least 28 weeks; they required pharmacological blood pressure control for severe hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg); and were able to swallow oral medications. Women were randomly assigned to receive (Prof: Mundle MD): Growity 10 mg oral nifedipine, 200 mg oral labetalol (hourly, in both of which the dose could be escalated if hypertension was Health Projects, New York, NY, maintained), or 1000 mg methyldopa (a single dose, without dose escalation). Masking of participants, study investigators, and care providers to group allocation was not possible because of different escalation protocols in the study groups. The primary outcome was blood pressure control (defined as 120-150 mm Hg systolic blood pressure and 70-100 mm Hg diastolic blood pressure) within 6 h with no adverse outcomes. This study is registered with Clinical Trials.gov, number NCT01912677, and the Clinical Trial Registry, India, number ctri/2013/08/003866.

Findings Between April 1, 2015, and Aug 21, 2017, we screened 2307 women for their inclusion in the study. We excluded 1413 (61%) women who were ineligible, declined to participate, had impending eclampsia, were in active and Children's Health, King's labour, or had a combination of these factors, 11 (4%) women in the nifedipine group, ten (3%) women in the labetalol group, and 11 (4%) women in the methyldopa group were ineligible for treatment (because they had only one qualifying blood pressure measurement) or had treatment stopped (because of delivery or transfer elsewhere). 894 (39%) women were randomly assigned to a treatment group and were included in the intention-to-treat analysis: Dr. Hillary Bracken, Gymulty 298 (33%) women were assigned to receive nifedipine, 295 (33%) women were assigned to receive labetalol, and 301 (33%) women were assigned to receive methyldopa. The primary outcome was significantly more common in women in the nifedipine group than in those in the methyldopa group (249 [84%] women vs 230 [76%] women; p=0.03). However, the primary outcome did not differ between the nifedipine and labetalol groups (249 [84%] women vs 228 [77%] women; p=0.05) or the labetalol and methyldopa groups (p=0.80). Seven serious adverse events (1% of births) were reported during the study: one (<1%) woman in the labetalol group had an intrapartum seizure and six (1%) neonates (one [<1%] neonate in the nifedipine group, two [1%] neonates in the labetalol group, and three [1%] neonates in the methyldopa group) were stillborn. No birth had more than one adverse event.

Interpretation All oral antihypertensives reduced blood pressure to the reference range in most women. As single


August 1, 2019 http://dx.doi.org/10.1016/ 50140-6736(19)31282-6

See Comment page 981 Department of Obstetrics and Gynecology, University of

Washington, Seattle, WA, USA (ProfT Easterling MD): Department of Obstetrics and Gynecology, Government Medical College, Nagpur, India USA (H Bracken PhD.

Prof B Winikoff MD)-

Gynaecology, Daga Memorial Women's Government Hospital, Nagpur, India (S Parvekar MD, S Mool DGO); and Department of Women College London, London, UK (Prof L A Magee MD,









https://pro.campus.sanofi/es/inteligencia-artificial/herramientas/top-herramientas-inteligencia-artificial-articulos-medicos

hypertension AND methyldopa AND labetalol



Methyldopa and labetalol are both medications used to treat hypertension, including high blood pressure during pregnancy.

Methyldopa is a centrally acting antihypertensive that lowers blood pressure by reducing sympathetic nervous system activity. It acts as an agonist at central inhibitory alpha-adrenergic receptors, resulting in decreased peripheral sympathetic tone and reduced arterial pressure. It lowers both standing and supine blood pressure, with effects beginning within 12 to 24 hours after oral administration. Methyldopa has been used since the 1960s and is still used in some settings for its low cost, although its use has largely been replaced by drugs with fewer side effects. It reduces systolic and diastolic blood pressure by about 13/8 mmHg compared to placebo. Common side effects include drowsiness, headache, and dry mouth. ncbi.nlm.nih +3


Labetalol is a beta blocker that also blocks alpha-adrenergic receptors, leading to decreased peripheral resistance and reduction of blood pressure. It slows heart rate and reduces the workload of the heart. Labetalol is commonly used to treat hypertension, including in pregnancy, and can be given orally or intravenously. It is considered effective and well-tolerated, often preferred in severe hypertension or when rapid blood pressure control is needed. Side effects may include dizziness, headache, and nausea.

**Provide Provided Provid


Comparative studies in pregnant women with hypertension show that oral labetalol is generally more effective than oral methyldopa in lowering systolic, diastolic, and mean arterial pressures. Labetalol-treated patients often achieve better blood pressure control and have more spontaneous




hypertension AND methyldopa AND labetalol ★ Responder Methyldopa reduces blood pressure in people with high blood Seleccionado pressure ncbi.nlm.nih ncbi.nlm.nih.gov/books/NBK551671 Methyldopa - StatPearls - NCBI Bookshelf Access provided by: Biblioteca Electrónica de Ciencia y Tecnología 📑 Review language : English 👽 Website language : English 🗈 Sign In DrugBank Also available in Cochrane Trusted evidence. go.drugbank.com/drugs/DB00968 English Español 日本語 Bahasa I Informed decisions. Library Better health Methyldopa: Uses, Interactions, Mechanism of Ac Browse Advanced search Methyldopa is a centrally-acting alpha-2 adrenergic agon Cochrane reviews -Searching for trials ▼ Clinical Answers ▼ About ▼ About Cochrane > combination with hydrochlorothiazide, and to treat hypert El idioma de su navegador es el español. Methyldopa is a medication that has bee Puede visualizar la Biblioteca Cochrane en español. Cambiar el idioma While there is some belief methyldopa re Cochrane Library cochrane.org/evidence/CD003... potential for this drug to cause adverse ϵ Cochrane Database of Systematic reviews Review - Intervention extent to which methyldopa reduces blo Methyldopa reduces blood pressure in people wi Unlock the full review Methyldopa for primary hypertension effect profile, and to determine the clinic Methyldopa is a medication that has been used to treat h revealed 12 trials with a total of 595 patie ☑ Greg T Mah, Aaron M Tejani, Vijaya M Musini Authors' declarations of interest belief methyldopa reduces blood pressure, there are cond Version published: 07 October 2009 Version history treatment arm (296 patients) or a placeb effects. The aim of this review was to determine the exten https://doi.org/10.1002/14651858.CD003893.pub3 @ methyldopa used in these studies ranged Cite this Collapse all Expand all daily dose of methyldopa was 750 mg da Abstract The Cochrane Database of Systematic Reviews weeks of therapy. None of the studies re Sign up to email alerts for topic pmc.ncbi.nlm.nih.gov/articles/PMC71... Available in English | Español | 日本語 methyldopa reduced the risk of having a Cited in 1 guideline Methyldopa for primary hypertension - PMC - Pubmed Contract Background Citations (1) Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive he Full text views: 2248 6 Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Methyldopa is a Methyldopa is a centrally acting antihypertensive agent, which was commonly used in the 1970's an centrally acting antihypertensive agent, which was commonly used in the 1970's and 80's for blood pressure control. Its use at Am score 11 blood pressure control. Its ... present has largely been replaced by antihypertensive drug classes with less side effects, but it is still used in developing Contents countries due to its low cost. A review of its relative effectiveness compared to placebo on surrogate and clinical outcomes is justified. **Abstract PICOs** Objectives Plain language summary Authors' conclusions To quantify the effect of methyldopa compared to placebo in randomized controlled trials (RCTs) on all cause mortality, Background cardiovascular mortality, serious adverse events, myocardial infarctions, strokes, withdrawals due to adverse effects and blood Objectives pressure in patients with primary hypertension. Methods Results Search methods



U academic



hoeltzenbein-et-al-pregnancy-outcome-after-first-trimester-use-of-methyldopa.pdf



The study "Pregnancy Outcome After First Trimester Use of Methyldopa" presents the largest prospective cohort analysis to date on the safety of methyldopa use during the first trimester in pregnant women with chronic hypertension. The study evaluated 261 pregnancies exposed to methyldopa compared with 526 pregnancies without chronic hypertension.

Key findings include:

- Major birth defects: The rate of major birth defects in the methyldopa group (3.7%) was
 slightly higher but not statistically significantly different from that in the comparison group
 (2.5%). The rates correspond to the general German population prevalence of about 3%. There
 was no clear pattern of specific birth defects attributable to methyldopa, and no strong
 evidence of teratogenicity was found.
- Spontaneous abortion: There was a tendency toward a higher rate of spontaneous abortions
 in the methyldopa-exposed group (17% versus 13%), but this was not statistically significant
 after adjustment and may be related to underlying bypertension or comorbidities rather than

Elicit



- ► Elicit simplifica el proceso de análisis de bibliografía médica al extraer datos clave de múltiples estudios. Compara resultados, identifica tendencias, sintetiza información relevante y evalúa la calidad de los estudios y permite tomar decisiones basadas en evidencia.
- Además, permite realizar revisiones sistemáticas y comparar metodologías de estudios científicos de manera automatizada. También dispone de un sistema de categorización avanzada que filtra estudios según su impacto y relevancia.



Features

Testimonials

Pricing

FAQ

Careers

Sign In

Sign Up

Analyze research papers at superhuman speed

Automate time-consuming research tasks like summarizing papers, extracting data, and synthesizing your findings.

Sign Up

TRUSTED BY RESEARCHERS AT
















Elicit









Report

Status

✓ Gar
50 s

Scr

10



Chat

AUGUST 7, 2025

Among pregnant women with gestational hypertension, what are the safety and efficacy profiles of labetalol and methyldopa in controlling blood pressure?

In treating gestational hypertension, labetalol demonstrates faster blood pressure control compared to methyldopa, with both drugs being effective but labetalol showing generally favorable safety outcomes for mothers and infants.

ABSTRACT

Labetalol tends to reduce blood pressure more quickly than methyldopa in pregnant women with gestational hypertension. * In four studies, labetalol led to a greater or faster decline in blood pressure—one trial reported control at 35.65 hours versus 43.46 hours with methyldopa, and another documented significantly faster reductions at 2, 4, and 6 hours (p < 0.01 to p < 0.001). * Two studies noted comparable blood pressure lowering with both drugs, while two others reported meaningful reductions in each group without a clear between-group difference. * One trial additionally observed that labetalol required fewer secondary interventions. *

Maternal safety profiles varied. * Several studies reported fewer adverse side effects with labetalol—one systematic review noted that drowsiness was more common with methyldopa—whereas one recent trial identified increased maternal hypotension with labetalol. * Neonatal outcomes also leaned in favor of labetalol in four studies, with reports of lower incidences of respiratory distress, preterm delivery, or small-for-gestational-age births; however, one study recorded higher rates of small-for-gestational-age infants, neonatal hyperbilirubinemia, hypotension, and intensive care admissions with labetalol. * Overall, the studies indicate that both drugs achieve significant blood pressure reduction, with labetalol showing advantages regarding speed of control and, in most studies, a favorable safety profile. *

METHODS

Among pregnant women with gestational hypertension, what are the safety and efficacy profiles of labetalol and methyldopa in controlling blood pressure?

In treating gestational hypertension, labetalol demonstrates faster blood pressure control compared to methyldopa, with both drugs being effective but labetalol showing generally favorable safety outcomes for mothers and infants.

Abstract

Labetalol tends to reduce blood pressure more quickly than methyldopa in pregnant women with gestational hypertension. In four studies, labetalol led to a greater or faster decline in blood pressure—one trial reported control at 35.65 hours versus 43.46 hours with methyldopa, and another documented significantly faster reductions at 2, 4, and 6 hours (p < 0.01 to p < 0.001). Two studies noted comparable blood pressure lowering with both drugs, while two others reported meaningful reductions in each group without a clear between-group difference. One trial additionally observed that labetalol required fewer secondary interventions.

Maternal safety profiles varied. Several studies reported fewer adverse side effects with labetalol—one systematic review noted that drowsiness was more common with methyldopa—whereas one recent trial identified increased maternal hypotension with labetalol. Neonatal outcomes also leaned in favor of labetalol in four studies, with reports of lower incidences of respiratory distress, preterm delivery, or small-for-gestational-age births; however, one study recorded higher rates of small-for-gestational-age infants, neonatal hyperbilirubinemia, hypotension, and intensive care admissions with labetalol. Overall, the studies indicate that both drugs achieve significant blood pressure reduction, with labetalol showing advantages regarding speed of control and, in most studies, a favorable safety profile.

Paper search


Using your research question "Among pregnant women with gestational hypertension, what are the safety and efficacy profiles of labetalol and methyldopa in controlling blood pressure?", we searched across over 126 million academic papers from the Semantic Scholar corpus. We retrieved the 50 papers most relevant to the query.

Screening


We screened in sources that met these criteria:

- Population: Does the study focus exclusively on pregnant women diagnosed with gestational hypertension (not chronic hypertension or mixed hypertensive disorders)?
- Intervention: Does the study evaluate labetalol and/or methyldopa as standalone treatments (not in combination with other antihypertensive medications)?
- Study Design: Is the study design either a randomized controlled trial, systematic review, or observational cohort study?
- Outcomes Comprehensiveness: Does the study report both blood pressure control AND maternal/fetal safety outcomes?
- Outcome Measurement Quality: Does the study include clear documentation of blood pressure measurements with specified methodology?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.








APRIL 18, 2025

What is the comparative effectiveness of labetalol versus methyldopa in managing blood pressure for women with pregnancy-induced hypertension?

In treating pregnancy-induced hypertension, labetalol achieved greater blood pressure reductions (70/36 mmHg vs 50/30 mmHg) and faster control (35-37 vs 42 hours) than methyldopa in most studies.

ABSTRACT


Ten studies (nine randomized controlled trials and one meta-analysis involving 2,200 women) compared labetalol and methyldopa for managing pregnancy-induced hypertension. * In seven of these studies, labetalol yielded greater blood pressure reductions and improved maternal outcomes. * For example, one trial reported that labetalol reduced systolic blood pressure by 70 mmHg and diastolic pressure by 36





Consensus



- Consensus evalúa el nivel de respaldo de un tema en la bibliografía científica. Su sistema de IA examina múltiples estudios y genera un análisis del grado de consenso en la comunidad científica sobre un hallazgo o tratamiento específico.
- Esta herramienta posibilita visualizar rápidamente los niveles de acuerdo entre diferentes estudios y filtrar resultados en función de su relevancia clínica. Además, incorpora una función de predicción basada en tendencias científicas, que ayuda a anticipar desarrollos futuros.







Pregnancy-induced hypertension (PIH) is a significant medical concern during pregnancy, contributing to maternal and fetal morbidity and mortality. Two commonly used antihypertensive medications for managing PIH are labetalol and methyldopa. This summary provides an overview of the efficacy and safety of these medications based on recent research findings.


Efficacy of Labetalol vs. Methyldopa

- Blood Pressure Control: Labetalol has been shown to reduce both systolic and diastolic blood pressure more
 rapidly and effectively than methyldopa in patients with pregnancy-induced hypertension. Studies consistently
 report a significant fall in mean arterial pressure (MAP) with labetalol compared to methyldopa, indicating
 superior efficacy in controlling blood pressure 1 2 4 6 9.
- Time to Control Blood Pressure: The time required to achieve optimal blood pressure control is generally shorter with labetalol compared to methyldopa. For instance, one study reported that the mean time to control blood pressure was approximately 36.97 hours with labetalol, compared to 42.22 hours with methyldopa 2 4 7.


Side Effects and Safety



Maternal Side Effects: Labetalol is associated with fewer maternal side effects compared to methyldona







Corpus ID: 22549257

Use of labetalol and methyldopa in pregnancy-

induced hy
G. Lamming, E. Symonds

TLDR Slight breathle
but drowsiness, head
and daily BP control

Publiced

R

Advanced

Figures an

View on PubMed

Clinical Trial > Br J Clin Pharmacol. 1979;8(Suppl 2):217S-222S.

Use of labetalol and methyldopa in pregnanc induced hypertension

G D Lamming, E B Symonds

PMID: 526404 PMCID: PMC1429744

Br. J. clin. Pharmac. (1979), 8, 217S-222S

USE OF LABETALOL AND METHYLDOPA IN PREGNANCY-INDUCED HYPERTENSION

G.D. LAMMING & E.M. SYMONDS

Department of Obstetrics and Gynaecology, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK

 Nineteen pregnant patients whose mean arterial pressure (MAP) was persistently ≥ 103.3 mmHg were given labetalol or methyldopa.

Log

- 2 Significant falls (P < 0.001) in BP only occurred in the group treated with labetalol, and daily BP control was better in this group.
- 3 Two severely hypertensive patients were successfully treated with intravenous labetalol.
- 4 There was a higher incidence of spontaneous labour in the labetalol group and a significant difference (P < 0.05) in the Bishop score of the cervix between the two groups.
- 5 There were no apparent detrimental effects on the foetus antenatally, during labour or post partum.
- 6 Slight breathlessness in one patient treated with labetalol was the only side-effect observed but drowsiness, headache and postural hypotension were reported in patients receiving methyldopa.


Introduction

THE use of anti-hypertensive agents in pregnancy is controversial. Most obstetricians agree that drug therapy has little place in the management of mild hypertension occurring late in the third trimester. Perinatal mortality has been shown to be lower in mild pregnancy-induced hypertensive patients than in the total hospital population (Symonds, 1979). When

study comparing the use of labetalol and methyldopa (Aldomet; Merck, Sharp & Dohme) in the treatment of pregnancy-induced hypertension. In addition two patients received intravenous labetalol as treatment for fulminating hypertension during pregnancy.

Mathada

OpenEvidence





Expanded question: What are

Labetalol and methyldopa induced hypertension, and

Labetalol is a non-selective effective in reducing the remeta-analysis found that I compared to placebo or nerisk of proteinuria/preecl However, there is some even small-for-gestational-age

Methyldopa, an alpha-2 ac

∃ References

1. <u>Oral Antihypertensive Treatment During Pregnancy: A Systematic Review and Network Meta-Analysis.</u>

Hup RJ, Damen JAA, Terstappen J, et al.

American Journal of Oldoi:10.1016/j.ajog.2025.0

- Maternal and Neonat Cohort Study.

Dublin S, Idu A, Avalos



Save

Email

> PLoS One. 2022 May 16;17(5):e0268284. doi: 10.1371/journal.pone.0268284. eCollection 2022.

Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: A retrospective cohort study

Sascha Dublin ^{1 2}, Abisola Idu ¹, Lyndsay A Avalos ³, T Craig Cheetham ⁴, Thomas R Easterling ⁵, Lu Chen ¹, Victoria L Holt ², Nerissa Nance ³, Zoe Bider-Canfield ⁶, Romain S Neugebauer ³, Kristi Reynolds ⁶, Sylvia E Badon ³, Susan M Shortreed ^{1 7}

Affiliations + expand

PMID: 35576217 PMCID: PMC9109931 DOI: 10.1371/journal.pone.0268284

FULL TEXT LINKS

Send to



Display options 🌣









Conclusión

- La inteligencia artificial ya no es una visión del futuro, sino una parte integral de nuestro presente. A medida que abrazamos las comodidades y mejoras que la IA aporta a nuestra vida diaria, es esencial mantenernos informados y conscientes de su impacto, a fin de aprovechar al máximo esta asombrosa tecnología mientras navegamos por un mundo cada vez más interconectado e inteligente.
- Las herramientas de IA en la búsqueda de artículos médicos permiten procesar grandes volúmenes de datos en tiempo récord. Identificando estudios relevantes y realizando síntesis de la evidencia disponible.

Muchas gracias

Fernanda.cuneo@fcm.unc.edu.ar